# US 2015/0147325 A1 · Serpin fusion polypeptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147325 A1
- Document ID: US20150147325A1
- Status: Published application
- Kind: A1
- Application number: 14/616,363
- Filed: 2015-02-06
- Published: 2015-05-28
- Earliest claimed: 2011-06-28
- Assignees: Inhibrx, Inc.
- Applicants: InhibRx LLC
- Inventors: Brendan P. Eckelman; John C. Timmer; Peter L. Nguy; Grant B. Guenther; Quinn Deveraux
- Web page: https://patentgrep.com/patent/US20150147325A1

## CPC

- C07K 14/8125: {Alpha-1-antitrypsin}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/76: Albumins
- C07K 14/765: Serum albumin, e.g. HSA
- C07K 14/811: {Serine protease (E.C. 3.4.21) inhibitors}
- C07K 14/8121: {Serpins}
- C07K 16/40: against enzymes
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.

## Claims

### Claim 1

An isolated fusion protein comprising at least one human serpin polypeptide operably linked to a second polypeptide wherein the second polypeptide comprises at least one the following:
an immunoglobulin Fc polypeptide or an amino acid sequence that is derived from an immunoglobulin Fc polypeptide;
a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide;
a WAP domain containing polypeptide or a sequence derived from a WAP domain containing polypeptide; or
an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide.

### Claim 2

An isolated fusion protein comprising at least one alpha-1 antitrypsin (AAT) polypeptide operably linked to a second polypeptide of at least one of the following:
an immunoglobulin Fc polypeptide;
a cytokine targeting peptide;
a human secretory leukocyte proteinase inhibitor (SLPI) polypeptide; and
an immunoglobulin Fc polypeptide and a human SLPI polypeptide, wherein the SLPI polypeptide comprises the WAP2 domain of human SLPI; or
a human serum albumin (HSA) polypeptide.

### Claim 3

An isolated fusion protein comprising at least one alpha-1 antitrypsin (AAT) polypeptide operably linked to a second polypeptide of at least one of the following:
an immunoglobulin Fc polypeptide;
a cytokine targeting peptide;
a human Elafin polypeptide;
a human Elafin polypeptide and an immunoglobulin Fc polypeptide, wherein the Elafin polypeptide comprises the WAP domain of human Elafin; or
a human serum albumin (HSA) polypeptide.

### Claim 4 (depends on 1)

The fusion protein of claim 1 wherein the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide or is derived from a human AAT polypeptide.

### Claim 5 (depends on 4)

The isolated fusion protein of claim 4, wherein AAT polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 6 (depends on 4)

The isolated fusion protein of claim 4, wherein the AAT polypeptide comprises the reactive site loop of AAT comprising the amino acid sequence of SEQ ID NO: 1 or a mutated reactive site loop of AAT comprising the amino acid sequence of SEQ ID NO: 32 or 33.

### Claim 7 (depends on 4)

The isolated fusion protein of claim 4, wherein the immunoglobulin Fc polypeptide is a human Fc polypeptide.

### Claim 8 (depends on 7)

The isolated fusion protein of claim 7, wherein human Fc polypeptide is a human IgM polypeptide or a human IgG Fc polypeptide.

### Claim 9 (depends on 8)

The isolated fusion protein of claim 8, wherein the human IgG Fc polypeptide is a human IgG1 polypeptide, a human IgG2 Fc polypeptide, human IgG3 Fc polypeptide, or human IgG4 Fc polypeptide.

### Claim 10 (depends on 1)

The isolated fusion protein of claim 1, wherein the immunoglobulin Fc polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 4, 5, and 7.

### Claim 11 (depends on 1)

The isolated fusion protein of claim 1, wherein the serpin polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

### Claim 12 (depends on 4)

The isolated fusion protein of claim 4, wherein the AAT polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

### Claim 13 (depends on 11)

The isolated fusion protein of claim 11, wherein the hinge region, the linker region or both the hinge region and the linker region comprise a peptide sequence.

### Claim 14 (depends on 1)

The isolated fusion protein of claim 1, wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.

### Claim 15 (depends on 1)

The isolated fusion protein of claim 1, wherein the cytokine targeting polypeptide is a human cytokine receptor polypeptide or a derivative of a human cytokine receptor polypeptide, a cytokine targeting polypeptide that binds a cytokine receptor or a cytokine targeting polypeptide binds a human cytokine.

### Claim 16 (depends on 15)

The isolated fusion protein of claim 15, wherein the human cytokine receptor polypeptide comprises multiple subunits.

### Claim 17 (depends on 15)

The isolated fusion protein of claim 15, wherein the human cytokine receptor is a receptor for TNF, IgE, IL-12, IL-23, IL-6, IL-1, IL-1, IL-17, IL-13, the p40 subunit of IL-12 and IL-23, IL-4, IL-10, IL-2, IL-18, IL-27, or IL-32.

### Claim 18 (depends on 17)

The isolated fusion protein of claim 17, wherein the cytokine receptor is a receptor for human TNF.

### Claim 19 (depends on 15)

The isolated fusion protein of claim 15, wherein the human cytokine is TNF, IgE, IL-12, IL-23, IL-6, IL-1, IL-1, IL-17, IL-13, the p40 subunit of IL-12 and IL-23, IL-4, IL-10, IL-2, IL-18, IL-27, or IL-32.

### Claim 20 (depends on 19)

The isolated fusion protein of claim 19, wherein the cytokine is human TNF.

### Claim 21 (depends on 15)

The isolated fusion protein of claim 15, wherein the cytokine targeting polypeptide is an antibody or an antibody fragment.

### Claim 22 (depends on 21)

The isolated fusion protein of claim 21, wherein the antibody or antibody fragment is chimeric, humanized, or fully human.

### Claim 23 (depends on 1)

The isolated fusion protein of claim 1, where the fusion protein comprises an amino acid sequence selected from SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27.

### Claim 24 (depends on 1)

The isolated fusion protein of claim 1, wherein the WAP domain containing polypeptide sequence comprises a SLPI polypeptide sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 9 and 10.

### Claim 25 (depends on 1)

The isolated fusion protein of claim 1, wherein the WAP domain containing polypeptide sequence comprises an elafin polypeptide sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, 12 and 13.

### Claim 26 (depends on 1)

The isolated fusion protein of claim 1, wherein the fusion protein comprises a serpin polypeptide, a WAP domain-containing polypeptide and an immunoglobulin Fc polypeptide such that at least two of the serpin polypeptide, the WAP domain-containing polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

### Claim 27 (depends on 2)

The isolated fusion protein of claim 2, wherein the fusion protein comprises an AAT polypeptide, a SLPI polypeptide and an immunoglobulin Fc polypeptide such that at least two of the AAT polypeptide, the SLPI polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

### Claim 28 (depends on 3)

The isolated fusion protein of claim 3, wherein the fusion protein comprises an AAT polypeptide, an Elafin polypeptide and an immunoglobulin Fc polypeptide such that at least two of the AAT polypeptide, the Elafin polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

### Claim 29 (depends on 4)

The isolated fusion protein of claim 4, wherein the fusion protein comprises two AAT polypeptides and an immunoglobulin Fc polypeptide.

### Claim 30 (depends on 29)

The isolated fusion protein of claim 29, wherein each of the two AAT polypeptides are operably linked to the immunoglobulin Fc polypeptide via a hinge region, a linker region, or both a hinge region and linker region such that the fusion protein has the structural arrangement from N-terminus to C-terminus as follows: AAT polypeptide-immunoglobulin Fc polypeptide-AAT polypeptide.

### Claim 31 (depends on 26)

The isolated fusion protein of claim 26, wherein the hinge region, the linker region or both the hinge region and the linker region comprise a peptide sequence.

### Claim 32 (depends on 2)

The isolated fusion protein of claim 2, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 28.

### Claim 33 (depends on 2)

The isolated fusion protein of claim 2, where the fusion protein comprises the amino acid sequence of SEQ ID NO: 29.

### Claim 34 (depends on 1)

The fusion protein of claim 1, wherein the albumin polypeptide is a human serum albumin (HSA) polypeptide or is derived from a HSA polypeptide.

### Claim 35 (depends on 34)

The isolated fusion protein of claim 34, wherein HSA polypeptide comprises the amino acid sequence of SEQ ID NO: 14 or the amino acid sequence of SEQ ID NO: 15.

### Claim 36 (depends on 34)

The isolated fusion protein of claim 34, wherein the HSA polypeptide comprises domain 3 of HSA.

### Claim 37 (depends on 34)

The isolated fusion protein of claim 34, wherein the serpin is operably linked to HSA via an albumin binding polypeptide.

### Claim 38 (depends on 2)

The isolated fusion protein of claim 2, wherein the AAT polypeptide is operably linked to HSA via an albumin binding polypeptide.

### Claim 39 (depends on 37)

The isolated fusion protein of claim 37, wherein the albumin binding polypeptide is an antibody or antibody fragment or derived from an antibody or antibody fragment.

### Claim 40 (depends on 39)

The isolated fusion protein of claim 39, wherein the antibody or antibody fragment or chimeric, humanized, or fully human.

### Claim 41 (depends on 37)

The isolated fusion protein of claim 37, wherein the albumin binding polypeptide is a peptide.

### Claim 42 (depends on 47)

The isolated fusion protein of claim 47, wherein the albumin binding polypeptide is Domain 3 of Streptococcal Protein G or a sequence derived from Domain 3 of Streptococcal Protein G.

### Claim 43 (depends on 1)

The isolated fusion protein of claim 1, wherein the serpin is covalently linked to a HSA polypeptide.

### Claim 44 (depends on 1)

The isolated fusion protein of claim 1, wherein the serpin is non-covalently linked to a HSA polypeptide.

### Claim 45 (depends on 1)

The isolated fusion protein claim 1, where the fusion protein comprises the amino acid sequence of SEQ ID NO: 30 or 31.

### Claim 46 (depends on 1)

The isolated fusion protein of claim 1, wherein the immunoglobulin Fc polypeptide is modified to enhance FcRn binding.

### Claim 47 (depends on 1)

The isolated fusion protein of claim 1, wherein the immunoglobulin Fc polypeptide comprising at least one of the following mutations: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu or Asn434Ser.

### Claim 48 (depends on 1)

A method of treating or alleviating a symptom of a disease or disorder associated with aberrant serine protease expression or activity in a subject in need thereof, the method comprising administering a fusion protein according to claim 1.

### Claim 49 (depends on 1)

A method of treating or alleviating inflammation or a symptom of an inflammatory disease or disorder while reducing the risk of infection, in a subject in need thereof, the method comprising administering a fusion protein according to claim 1.

### Claim 50 (depends on 1)

A method of reducing the risk of infection in a subject in need thereof, the method comprising administering a fusion protein according to claim 1.

### Claim 51 (depends on 48)

The method of claim 48, wherein the subject is a human.

### Claim 52 (depends on 49)

The method of claim 49, wherein the inflammatory disease or disorder is selected from the following: emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia-reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, Systemic lupus erythematosus, and Multiple sclerosis.

### Claim 53 (depends on 50)

The method of claim 50, wherein the infection is selected from bacterial infections, fungal infections, or viral infections.
